This was a preliminary comparative study conducted on 62 patients with functional IDA and moderate CKD, randomized to treatment with three different iron sources for oral administration, where, in addition to the iron blood parameters used to demonstrate treatment efficacy, CRP and hepcidin values were evaluated to deepen our understanding of the effect of therapy on inflammatory status and its involvement in iron homeostasis, which is strictly related to hepcidin levels in the body. The gene discussed is HAMP; the disease is chronic kidney disease.